home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

50.15 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

22 23 Next >

Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation. ↗

October 13, 2023

EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive.

Via Chartmill

14 Analysts Have This to Say About Exelixis ↗

October 11, 2023

Via Benzinga

Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains ↗

October 02, 2023

Low-beta stocks provide an avenue for investors looking for long-term growth accompanied by low volatility.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2023 ↗

September 26, 2023

Via Benzinga

2 Top Biotech Stocks Defying the Bear Market ↗

September 15, 2023

The best may be yet to come for these companies.

Via The Motley Fool

The Latest Analyst Ratings for Exelixis ↗

September 13, 2023

Via Benzinga

3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall ↗

September 20, 2023

Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.

Via InvestorPlace

Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy ↗

September 16, 2023

Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule...

Via Talk Markets

4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

September 16, 2023

A 14% decline in the Nasdaq Composite represents the perfect opportunity for investors to pounce.

Via The Motley Fool

Topics Stocks

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

September 12, 2023

From Exelixis, Inc.

Via Business Wire

Where Exelixis Stands With Analysts ↗

August 22, 2023

Via Benzinga

Analyst Expectations for Exelixis's Future ↗

August 02, 2023

Via Benzinga

Exelixis (EXEL) Q2 2023 Earnings Call Transcript ↗

August 02, 2023

EXEL earnings call for the period ending June 30, 2023.

Via The Motley Fool

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September

August 31, 2023

From Exelixis

Via Business Wire

The Top Healthcare Stocks to Buy With $100 ↗

August 30, 2023

Both stocks have outperformed the broader market in the last 12 months.

Via The Motley Fool

Exelixis Inc. (NASDAQ: EXEL) Sets New 52-Week High in Tuesday Session

August 29, 2023

Via Investor Brand Network

Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest ↗

August 24, 2023

Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the...

Via Benzinga

Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

August 24, 2023

From Exelixis, Inc.

Via Business Wire

2 No-Brainer Biotech Stocks to Buy Right Now ↗

August 24, 2023

These two companies make a compelling case for a high price.

Via The Motley Fool

Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

August 23, 2023

From Exelixis, Inc.

Via Business Wire

These Are the ONLY 3 Biotech Stocks to Consider in August 2023 ↗

August 21, 2023

These biotech stocks to buy represent tremendous bets and are essentially fueling innovation and portfolio growth at the same time.

Via InvestorPlace

Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients ↗

August 21, 2023

Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs

Via Benzinga

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

August 21, 2023

From Exelixis, Inc.

Via Business Wire

3 Strong Biotech Performers To Watch As Sector Nears Breakout

August 17, 2023

As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming.

Via MarketBeat

Topics ETFs

Exelixis Stock Sees Rising Relative Strength Rating ↗

August 14, 2023

On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before.

Via Investor's Business Daily

3 Biotech Stocks You’ll Regret Not Buying Soon ↗

August 08, 2023

These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023 ↗

August 08, 2023

Via Benzinga

Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update

August 01, 2023

From Exelixis, Inc.

Via Business Wire

Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil ↗

July 29, 2023

There is opportunity in a crisis. Key biotech stocks amid turmoil could be the greatest deals on the market today.

Via InvestorPlace

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com